The webinar will feature a presentation from an expert in the field of idiopathic pulmonary fibrosis (IPF), who will discuss the current treatment landscape and unmet medical need in treating patients with chronic cough associated with IPF.

The Trevi management team will discuss the recently reported interim data from the Phase 2 Cough And NALbuphine (CANAL) Trial of Haduvio™ (oral nalbuphine ER) in this condition.

Chronic cough has been experienced in up to 85% of IPF patients and is considered one of the most debilitating symptoms. Haduvio™ is currently the lead investigational therapy in development for this unmet need with a unique dual mechanism of action.

A live question and answer session will follow.